DPP-4s’ Prime Advantage Is Pancreatic Safety Profile, Bristol Says
The ability to preserve pancreatic function is the primary competitive advantage for DPP-4 inhibitors relative to sulfonylureas, according to Bristol-Myers Squibb Senior VP-Global Clinical Development Brian Daniels. Bristol is initially developing DPP-4 inhibitors for diabetes
You may also be interested in...
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.